“Close Then Clear” Margins in Transoral Resection of p16+ Oropharyngeal Squamous Cell Carcinoma
Otolaryngology–Head and Neck Surgery · 2025
DOI: 10.1002/ohn.70032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Otolaryngology–Head and Neck Surgery, 2025. Verfasst von Chrisje Den Besten und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Dalhousie University, Halifax, Nova Scotia, Canada. Hauptthemen laut MEDLINE: Oropharyngeal Neoplasms, Margins of Excision, Robotic Surgical Procedures, Squamous Cell Carcinoma of Head and Neck. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
Standard 5‐mm surgical margins in the oropharynx are challenging due to the intimate relationship with neurovascular structures and patient function. De‐escalation of therapy with the acceptance of close surgical margins may improve functional patient outcomes. This study assesses locoregional recurrence with initial close (≤2 mm) margins following transoral surgery for p16+ oropharyngeal squamous cell carcinoma (SCC) with or without re‐resection and adjuvant therapy. Study Design Retrospective cohort study.
Setting
Canadian tertiary care center.
Methods
Retrospective chart review of all patients who underwent transoral robotic surgery or transoral laser microsurgery with curative intent for p16+ oropharyngeal SCC and had ≤2 mm initial surgical margins with or without re‐resection and adjuvant therapy between January 2019 and December 2023. The primary outcome was 2‐year locoregional control.
Results
In total, 80 patients were included; 54 had a 2‐year follow‐up available. Initial margins were close (≤2 mm) in 44 patients (55%) and positive in 34 patients (42.5%). Re‐resection was performed in 67 patients (83.8%). Following re‐resections, three patients (3.8%) had positive margins and 77 (96.2%) had close or clear margins. Deep margins were most involved (67.5%). In total, 42 patients (52.5%) received adjuvant (chemo)‐radiotherapy. Amongst the 54 patients eligible for 2‐year follow‐up, one had regional recurrence at 18 months postsurgery, resulting in a 2‐year locoregional control rate of 98.1%. Conclusion p16+ oropharyngeal SCC with close initial surgical margins results in low locoregional recurrence rates. Intraoperative re‐resection with acceptance of close surgical margins may be an effective strategy to preserve both oncologic safety and functional outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Dalhousie University, Halifax, Nova Scotia, Canada.
- Department of Otolaryngology-Head and Neck Surgery, Haaglanden MC, The Hague, The Netherlands.
- Department of Otolaryngology-Head and Neck Surgery, Wellington Hospital, Wellington, New Zealand.
- Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada.
ORCID-Profile: Kalpesh Hathi
Zitieren
APA
Den Besten, C., Hathi, K., MacKay, C., Patel, D., Bullock, M. J., Rigby, M. H., Taylor, S. M., Trites, J. R., & Corsten, M. (2025). “Close Then Clear” Margins in Transoral Resection of p16+ Oropharyngeal Squamous Cell Carcinoma. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.70032
Vancouver
Den Besten C, Hathi K, MacKay C, Patel D, Bullock MJ, Rigby MH, et al. “Close Then Clear” Margins in Transoral Resection of p16+ Oropharyngeal Squamous Cell Carcinoma. Otolaryngology–Head and Neck Surgery. 2025. doi:10.1002/ohn.70032
BibTeX
@article{DenBesten2025,
author = {Den Besten, Chrisje and Hathi, Kalpesh and MacKay, Colin and Patel, Depak and Bullock, Martin J and Rigby, Matthew H and Taylor, S Mark and Trites, Jonathan R and Corsten, Martin},
title = {“Close Then Clear” Margins in Transoral Resection of p16+ Oropharyngeal Squamous Cell Carcinoma},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2025},
doi = {10.1002/ohn.70032}
}
EUVIMED